Research Guides
18 in-depth guides covering peptide comparisons, roundups, and research deep-dives.
AI Peptide Design for GPCRs: What the 2026 Benchmark Found
A critical analysis of the 2026 GPCR peptide-design benchmark, including confidence overestimation, training-set effects, sequence design, and validation limits.
BPC-157 vs TB-500: Mechanism and Evidence Comparison
Compare BPC-157 and TB-500 mechanisms, evidence, and safety profiles. See which peptide is best for tendon, muscle, and gut repair based on research.
CJC-1295 vs Ipamorelin: GH Peptide Comparison
Compare CJC-1295 and Ipamorelin mechanisms, GH release profiles, and safety. Learn the differences between GHRH analogs and GHRPs for growth hormone research.
Cognitive Enhancement Research Compounds Compared: Semax, Selank, and NAD+ Precursors
Compare Semax, Selank, and NAD+ precursors for cognitive enhancement research, including mechanisms, human evidence, limitations, and endpoint selection.
EWSR1-FLI1 Peptide Vaccine in Metastatic Ewing Sarcoma: What a 2026 Case Report Shows
A critical analysis of the August 2026 first-in-human EWSR1-FLI1 fusion-breakpoint peptide vaccine case report, its immune findings, and its limits.
GHK-Cu vs BPC-157: Wound Healing Peptide Comparison
Compare GHK-Cu and BPC-157 for wound healing, tissue repair, and anti-aging. Learn how these peptides work through different mechanisms — copper binding vs systemic protection.
Growth Hormone Axis Explained: GHRH, Ghrelin, GH, and IGF-1
An evidence-based guide to the growth hormone axis, including GHRH, somatostatin, ghrelin receptor signaling, pulsatile GH release, GHR, IGF-1, and peptide secretagogues.
Incretin Weight Loss and Body Composition: What the 2026 Evidence Shows
A research review of lean-mass, fat-mass, and function evidence for semaglutide, tirzepatide, liraglutide, and other incretin-based weight-loss therapies.
Liraglutide Did Not Preserve Residual C-Peptide in Long-Standing Type 1 Diabetes: What a 2026 Pilot RCT Shows
A critical analysis of a new 18-person randomized trial testing liraglutide and residual beta-cell function in long-standing type 1 diabetes.
Metabolic Regulation and Peptide Signaling: AMPK, mTOR, and Mitochondrial Crosstalk
Explore how peptide signals interact with AMPK, mTOR, insulin, growth hormone, and mitochondrial pathways to regulate cellular and whole-body metabolism.
MOTS-c in Sepsis-Induced Cardiomyopathy: Evidence Review (August 2026)
An August 2026 review of direct MOTS-c evidence in sepsis-induced cardiomyopathy, proposed AMPK and endothelial pathways, and translation gaps.
MOTS-c Is a Mitochondrial-Encoded Host Defense Peptide: What the 2026 eLife Version Shows
A critical analysis of the 2026 MOTS-c host-defense study, including bacterial membrane effects, mouse MRSA evidence, macrophage data, and limits.
NAD+ vs MOTS-c: Longevity Peptide Comparison
Compare NAD+ and MOTS-c mechanisms for aging and longevity. Learn how these compounds work through different cellular pathways — NAD+ for sirtuins and MOTS-c for AMPK.
OL-RA11 Frog Peptide Linked Autophagy to Wound Repair in Mice: What the 2026 Study Shows
A critical analysis of the August 2026 OL-RA11 study, including mouse wound closure, macrophage autophagy, keratinocyte Wnt signaling, and limits.
Peptide Pharmacokinetics and Bioavailability: Half-Life, Stability, and Absorption
Learn how peptide half-life, proteolytic stability, absorption, distribution, clearance, formulation, and assay design shape bioavailability and research interpretation.
Peptide Receptor Desensitization and Cycling: Research Guide
Learn how peptide receptor desensitization, tolerance, and cycling are studied across GH secretagogues and related compounds. Review mechanisms, risk factors, and evidence-based protocol design considerations.
Semax vs Selank: Nootropic Peptide Comparison
Compare Semax and Selank mechanisms, evidence, and effects. Learn which nootropic peptide is better for focus, anxiety, and cognitive enhancement.
TE-8214 Extended Octreotide Exposure to 5.5 Days: What the 2026 Phase 1 Study Shows
A critical analysis of the 2026 TE-8214 Phase 1 study, including dual-fatty-acid albumin binding, 5.5-day half-life, IGF-1 findings, and limits.